Long-term results with cisapride in Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
W H Jost, K Schimrigk

Abstract

In this study, we examined whether there is a long-term effect of cisapride on colonic transit in Parkinson's disease. Twenty-five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.

References

Dec 11, 1991·Klinische Wochenschrift·W H Jost, K Schimrigk
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·L EdwardsR F Pfeiffer
Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·C SingerW J Weiner
Jul 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·W H Jost, K Schimrigk
Nov 1, 1995·The Annals of Pharmacotherapy·V Y GardnerC A Heyneman

❮ Previous
Next ❯

Citations

Dec 19, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·T E Eichhorn, W H Oertel
May 13, 2011·Journal of Neurology·Tjalf ZiemssenBirgit Herting
Mar 11, 2008·Journal of Neural Transmission·R SakakibaraT Hattori
Jul 10, 2003·Lancet Neurology·Ronald F Pfeiffer
Jun 2, 2007·Proceedings. Biological Sciences·Marc D HauserJustin Wood
Dec 18, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·K WingeL M Werdelin
Feb 27, 2013·Clinical Interventions in Aging·Beatriz Gras-Miralles, Filippo Cremonini
Jun 2, 2012·World Journal of Gastroenterology : WJG·Masahiro TajikaKenji Yamao
May 24, 2011·Parkinson's Disease·Ariane Park, Mark Stacy
Jun 16, 2011·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D Salat-FoixO Suchowersky
Sep 16, 2011·Parkinson's Disease·Ryuji SakakibaraTomonori Yamanishi
Feb 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Dag Nyholm, Hans Lennernäs
Dec 30, 2014·Expert Opinion on Pharmacotherapy·Malco RossiSantiago Perez-Lloret
Dec 25, 2010·Therapeutic Advances in Neurological Disorders·Tjalf Ziemssen, Heinz Reichmann
May 8, 2001·European Journal of Gastroenterology & Hepatology·P H WieselM A Kamm
Oct 27, 2018·Current Treatment Options in Gastroenterology·Chethan RamprasadBaharak Moshiree
Jan 20, 2018·Current Gastroenterology Reports·Amol SharmaSatish S C Rao
Feb 19, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Zhi LiuTakamichi Hattori
Mar 24, 2005·The American Journal of Gastroenterology·Davendra Ramkumar, Satish S C Rao
Feb 19, 2020·Expert Opinion on Emerging Drugs·Dinkar KulshreshthaMandar Jog
Oct 19, 2006·British Journal of Community Nursing·Anna Bywater, Alison While
Mar 22, 2018·NPJ Parkinson's Disease·Anna J Pedrosa CarrascoDavid J Pedrosa
Mar 7, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Jose-Alberto Palma, Horacio Kaufmann
Jul 12, 2007·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·J M SolerE Chartier-Kastler
Sep 1, 2011·Progress in Neurobiology·Philippe HuotJonathan M Brotchie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
W H Jost, K Schimrigk
Movement Disorders : Official Journal of the Movement Disorder Society
Zhi LiuTakamichi Hattori
Movement Disorders : Official Journal of the Movement Disorder Society
R DjaldettiE Melamed
Movement Disorders : Official Journal of the Movement Disorder Society
R SakakibaraTakamichi Hattori
Movement Disorders : Official Journal of the Movement Disorder Society
W D NeiraJ G de Yébenes
© 2021 Meta ULC. All rights reserved